skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Patent ·
OSTI ID:1986773

The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.

Research Organization:
Univ. of California, Davis, CA (United States)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
DOE Contract Number:
SC0002061; 1RC4EB012836-01
Assignee:
The Regents of the University of California (Oakland, CA)
Patent Number(s):
11,485,758
Application Number:
17/131,324
OSTI ID:
1986773
Resource Relation:
Patent File Date: 12/22/2020
Country of Publication:
United States
Language:
English

References (58)

The Epithelial Integrin αvβ6 Is a Receptor for Foot-and-Mouth Disease Virus journal January 2000
Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin  v 6 Expression with Positron Emission Tomography journal August 2007
Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis journal June 2016
Modified plant viruses as vectors patent August 2000
Fluorescent Amphiphilic PEG‐Peptide‐PEG Triblock Conjugate Micelles for Cell Imaging journal March 2014
Flexibility of the Major Antigenic Loop of Foot-and-Mouth Disease Virus Bound to a Fab Fragment of a Neutralising Antibody: Structure and Neutralisation journal March 1999
Rgd and Other Recognition Sequences for Integrins journal November 1996
Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide journal January 2007
A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzene-sulphonic acid journal March 1976
Structure and receptor binding journal January 2003
Effect of pegylation on pharmaceuticals journal March 2003
The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution journal February 1989
Targeted In vivo Imaging of Integrin  v 6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model journal June 2009
Effective drug delivery by PEGylated drug conjugates journal February 2003
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide journal April 2004
Exact and approximate rebinning algorithms for 3-D PET data journal April 1997
Bio-Functionalized Stimulus-Responsive Dissolvable Peg-Hydrogels patent-application November 2013
Identification of Pancreatic Cancer Stem Cells journal February 2007
Absence of αvβ6 Integrin Is Linked to Initiation and Progression of Periodontal Disease journal May 2008
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies journal October 2006
Alpha(v)beta(6) integrin-binding peptides and methods of use thereof patent November 2021
Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival journal January 2007
Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness journal August 2005
Immunomodulatory peptides patent December 2014
Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides journal March 2002
Bioactive hydrogels made from step-growth derived PEG–peptide macromers journal May 2010
Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery journal March 2011
Radiolabeled Multimeric Cyclic RGD Peptides as Integrin α v β 3 Targeted Radiotracers for Tumor Imaging journal July 2006
Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction. journal July 1990
Definition of an Unexpected Ligand Recognition Motif for αvβ6 Integrin journal January 1999
PEGylation, successful approach to drug delivery journal November 2005
PET/CT: Form and Function journal February 2007
Chemistry for peptide and protein PEGylation journal June 2002
18Fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer journal May 1999
Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma journal January 2005
αvβ6-Fyn Signaling Promotes Oral Cancer Progression journal October 2003
Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. journal March 1992
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation journal January 2004
Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment journal February 2004
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro journal September 2004
Specificity of the VP1 GH Loop of Foot-and-Mouth Disease Virus for αv Integrins journal October 2006
Bi-terminal pegylated integrin-binding peptides and methods of use thereof patent February 2021
PEG–Peptide Conjugates journal April 2014
A Peptide Selected by Biopanning Identifies the Integrin  v 6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer journal June 2007
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. journal December 1993
Long-term survival after pancreatic cancer treatment journal October 2007
Diagnosis of pancreatic carcinoma: role of FDG PET. journal December 1998
Structure of a major immunogenic site on foot-and-mouth disease virus journal April 1993
Integrin Structure, Activation, and Interactions journal January 2011
Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. journal March 1994
Antibody-Mediated Blockade of Integrin αvβ6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor-β–Regulated Mechanism journal January 2008
Implications of PET based molecular imaging on the current and future practice of medicine journal January 2004
High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner journal April 1998
The dawning era of polymer therapeutics journal May 2003
Solid-Phase Synthesis of 2-[ 18 F]Fluoropropionyl Peptides journal July 2006
Effects of PEG conjugation on insulin properties journal June 2002
The Effect of Bi-Terminal PEGylation of an Integrin  v 6-Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake journal March 2015
Preoperative evaluation of pancreatic adenocarcinoma journal July 2008

Related Subjects